Impact of fremanezumab on disability outcomes in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies

Impact of fremanezumab on disability outcomes in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies

Abstract Background Migraine is the second leading cause of disability worldwide. Although many preventive treatments reduce migraine frequency and severity, it is unclear whether these treatments reduce migraine-related disability in a clinically meaningful way. This pooled analysis evaluated the a...

Full description

Bibliographic Details
Main Authors: Peter McAllister, Joshua M. Cohen, Verena Ramirez Campos, Xiaoping Ning, Lindsay Janka, Steve Barash
Format: Article
Language:English
Published: BMC 2022-08-01
Series:The Journal of Headache and Pain
Subjects:
Migraine
Disability
MIDAS
HIT-6
Fremanezumab
Preventive
Online Access:https://doi.org/10.1186/s10194-022-01438-4

Internet

https://doi.org/10.1186/s10194-022-01438-4

Similar Items